INMB FY 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000-91.0% YoY

Gross Profit

$14,000100.0% margin

Operating Income

-$43M-304535.7% margin

Net Income

-$42M-300585.7% margin

EPS (Diluted)

$-2.11

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$40M

Total Liabilities

$7M

Stockholders' Equity

$32M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$155,000	-91.0%
Gross Profit	$14,000	$155,000	-91.0%
Operating Income	-$43M	-$30M	-43.4%
Net Income	-$42M	-$30M	-40.2%